Wingstop is a solid long-term model and an easy double over time, though it will not rebound quickly. Its decline stems mainly from same-store sales down more than 8% in Q1 2026 as lower-income consumers pull back amid inflation, high gas prices and trading down; GLP-1 drugs are a smaller headwind since most customers don't fit that demographic. Growth is normalizing after explosive years and guidance was cut, but aggressive unit expansion continues. Recovery could take a few years. x.com x.com x.comÂ